Newsletters

[Proceedings of the National Academy of Sciences of the United States of America] Investigators developed a scalable embryonic stem cell–based platform for efficient production of mitochondrial DNA mutant mice.

[Cell Death & Disease] Researchers presented a role of epithelial cell adhesion molecule (EpCAM) in exit from pluripotency of murine ESCs to establish cardiomyocytes in embryoid bodies.

[Stem Cell Reports] Investigators developed a robust protocol that generates functional stem cell-derived islets from all eight tested hPSC lines.

[Stem Cell Reviews and Reports] Researchers presented a protocol for generating cortical organoids integrated with microglial progenitors derived from hESCs by differentiating hESCs into Yolk Sac Embryoid Bodies.

[iScience] The authors showed that transplantation of the hiPSC-derived cardiomyocyte patch onto the damaged heart after myocardial infarction increases the ratio of collagen type I against collagen type III to modulate alignment of the collagen fibers at the infarcted zone.

[FEBS Journal] Scientists showed that Plk1-interacting checkpoint helicase (PICH) deficiency induces genomic instability and drastically reduces the efficiency of iPSC generation.

[ACS Biomaterials Science & Engineering] A parylene-C coating was deposited onto binary colloidal crystals to generate imprinted substrates with concave bowl-like micro/nanotopographies possessing multidirectional symmetry.

[Gene Therapy] Scientists isolated urinary epithelial cells from a Wilson disease patient carrying the ATP7B H1069Q mutation were reprogrammed into iPSCs.

[Experimental & Molecular Medicine] The authors summarize this progress and outline a practical road map to accelerate the development of precise human models and advanced hPSC-based cell therapies for Parkinson’s disease.

[Syracuse University Today] Biomedical and chemical engineer Zhen Ma uses human stem cells to create 3D heart models that could accelerate drug screening and personalize patient care.

[ReviR Therapeutics] ReviR Therapeutics announced a strategic investment from CureCMT to support the launch of a precision medicine platform for Charcot-Marie-Tooth disease (CMT).

[Asahi Kasei] Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases.